Homology Medicines Inc
Change company Symbol lookup
Select an option...
FIXX Homology Medicines Inc
APAM Artisan Partners Asset Management Inc
TQQQ ProShares UltraPro QQQ
AVCT American Virtual Cloud Technologies Inc
LITM Snow Lake Resources Ltd
SJ Scienjoy Holding Corp
PBTS Powerbridge Technologies Co Ltd
DRTT DIRTT Environmental Solutions Ltd
LVTX LAVA Therapeutics NV
AGNPF Algernon Pharmaceuticals Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

Closing Price
$1.52
Day's Change
-0.03 (-1.94%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.62
Day's Low
1.51
Volume
(Light)
Volume:
140,198

10-day average volume:
258,067
140,198

Crown Castle International Corp. Stock Underperforms Thursday When Compared To Competitors

4:42 pm ET July 7, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Crown Castle International Corp. CCI sank 0.08% to $171.64 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.50% to 3,902.62 and the Dow Jones Industrial Average DJIA rising 1.12% to 31,384.55. Crown Castle International Corp. closed $38.23 short of its 52-week high ($209.87), which the company reached on December 31st.

The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as America Movil S.A.B. de C.V. Series A AMXA rose 2.20% to $20.41, SBA Communications Corp. SBAC fell 0.24% to $326.33, and American Tower REIT AMT fell 0.41% to $257.18. Trading volume (1.2 M) remained 621,121 below its 50-day average volume of 1.8 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 7, 2022.

	

(END) Dow Jones Newswires

July 07, 2022 16:42 ET (20:42 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.